Etrolizumab

Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) [1][2].

Product Specifications

CAS Number

[1044758-60-2]

Product Name Alternative

RhuMAb Beta7; RG7413; PRO145223

UNSPSC

12352203

Target

Integrin

Type

Inhibitory Antibodies

Related Pathways

Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/etrolizumab.html

Purity

99.56

Solubility

10 mM in DMSO

Smiles

[Etrolizumab]

Molecular Weight

(144.3 kDa)

References & Citations

[1]Tang MT, et, al. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jun;47 (11) :1440-1452.|[2]Stefanich EG, et, al. A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol. 2011 Apr;162 (8) :1855-70.